Characterization of distinct microbiota associated with androgenetic alopecia patients treated and untreated with platelet-rich plasma(PRP)

Background:Androgenic alopecia(AGA)is the most common type of hair loss in men,and there are many studies on the treatment of hair loss by platelet-rich plasma(PRP).The human scalp contains a huge microbiome,but its role in the process of hair loss remains unclear,and the relationship between PRP and the microbiome needs further study.Therefore,the purpose of this study was to investigate the effect of PRP treatment on scalp microbiota composition.Methods:We performed PRP treatment on 14 patients with AGA,observed their clinical efficacy,and collected scalp swab samples before and after treatment.The scalp microflora of AGA patients before and after treatment was characterized by amplifying the V3-V4 region of the 16 s RNA gene and sequencing for bacterial identification.Results:The results showed that PRP was effective in the treatment of AGA patients,and the hair growth increased significantly.The results of relative abundance analysis of microbiota showed that after treatment,g_Cutibacterium increased and g_Staphylococcus decreased,which played a stable role in scalp microbiota.In addition,g_Lawsonella decreased,indicating that the scalp oil production decreased after treatment.Conclusions:The findings suggest that PRP may play a role in treating AGA through scalp microbiome rebalancing.

The Pathogenesis and Treatment Progress of Androgenic Alopecia

Androgenic alopecia, also known as seborrheic alopecia, is the most common hair loss disorder in dermatology clinics, mainly characterized by hair follicle miniaturization and progressive hair loss. The etiology and pathogenesis of androgenic alopecia are not clear, but may be related to heredity and androgen metabolism. Currently, minoxidil and finasteride are the only two drugs approved by the U.S. Food and Drug Administration (FDA) for AGA treatment, other treatments include oral minoxidil, hair transplantation, low energy laser therapy (LLLT), platelet-rich plasma (PRP), Chinese medicine microneedles, and combination therapy. With the development of medicine and science, we have ushered in the era of biologics and targeted therapy. In recent years, a variety of signaling pathways for androgenic alopecia have been found, which may provide a basis for targeted therapy for androgenic alopecia.

Psychological stress impact neurotrophic factor levels in patients with androgenetic alopecia and correlated with disease progression

BACKGROUND Androgenetic alopecia(AGA)is a common form of hair loss that can be influenced by psychological factors.AIM To investigate the impact of mental stress on neurotrophic factors in patients with AGA and correlate the findings with the progression of AGA.METHODS A total of 120 patients with AGA were analyzed in this study,which were divided into a non-stress group(n=30)and a stress group(n=90)on the basis of the presence or absence of psychological stress confirmed by Depression Anxiety Stress Scale-21 scale.The baseline demographic characteristics,serum cortisol levels,hair growth parameters,neurotrophic factors,and AGA progression scores between the non-stress and stress groups were compared.Correlation analyses were conducted to assess the relationships among stress,neurotrophic factors,hair loss progression,and AGA progression.RESULTS This study revealed significantly higher cortisol levels throughout the day in the stress group than in the non-stress group.The stress group exhibited lower levels of nerve growth factor,brain-derived neurotrophic factor,and glial cell linederived neurotrophic factor and higher expression levels of neurotrophin(NT)-3 and NT-4 than the non-stress group.Hair parameters indicated lower hair diameter,decreased hair density,and more severe AGA grading in the stress group,whereas follicle count and terminal/vellus hair ratio showed no significant differences between the two groups.After 1 year of treatment with 5%minoxidil,efficacy was observed to be lower but AGA progression was notably more pronounced in the stress group than in the non-stress group.Disease progression was positively correlated with high stress and NT-4 levels.CONCLUSION This study provides compelling evidence of the influence of mental stress on neurotrophic factors and its correlation with the progression of AGA.The findings underscore the need for a comprehensive approach to the management of AGA that considers the physiological and psychosocial aspects.Further research is warranted to validate the findings and explore targeted therapeutic interventions for individuals with stress-related AGA.

Re-Densification Effect of Pressure-Injected Peptide-Hyaluronic Acid Combination on Male Androgenic Alopecia

Introduction: Mechanism of male androgenic alopecia (MAGA) is complex and leads to an excessive hair shedding and decreased hair density. Oral, topical, and injectable autologous treatments demonstrate ability to stimulate hair re-growth, but the response is suboptimal or plateaus off. Synthetic combination of the peptide complex and hyaluronic acid (P-HA) demonstrated hair regrowth in alopecia patients. Electronically-operated pneumatic injections (EPI) generate micro-trauma in the dermis and under wound-healing conditions may enhance regeneration effect of P-HA. Methods: Subjects seeking improvement of their male pattern hair loss (Hamilton-Norwood type 2-4) received the P-HA treatments through EPI. The course included 4 treatments every two weeks over the 8-week period. In 6 months, the hair growth was assessed comparative to baseline by global clinical photography and digital phototrichograms. The treatment safety and tolerability were documented through the whole study period. Results: Twelve men (30-45 years old) completed the treatment course with high tolerability and without adverse events. Post-treatment assessment of the previously bald areas showed improved coverage on the clinical photographs. The phototrichograms demonstrated statistically significant increase in terminal hair density by 36%, cumulative hair thickness by 37%, and follicular units by 20%;all contributing to a 38% increase in cumulated hair density (all p Conclusion: Electronic pneumatic injections are well tolerated and can be safely used for the needle-free administration of the peptide-hyaluronic acid combination in MAGA therapy. We achieved significant hair re-densification in the balding scalp. The exact role of the EPI-induced impact in the hair re-growth mechanism remains to be ascertained. .

Evaluation of the Clinical Efficacy of Chuzhi Shengfa Tablets and Finasteride in the Treatment of Androgenetic Alopecia

Objective:To explore the clinical efficacy and safety of Chuzhi Shengfa tablets combined with finasteride in the treatment of male androgenetic alopecia(AGA).Methods:Sixty male patients with androgenetic alopecia admitted to our Department of Dermatology between January 2022 and January 2024 were randomly divided into two groups,with 30 patients in each group.The control group was treated with finasteride,while the observation group received a combination of Chuzhi Shengfa tablets and finasteride.The clinical efficacy and adverse reactions in both groups were compared.Results:The overall effectiveness rate in the observation group was 93.33%(28/30),significantly higher than the control group’s 73.33%(22/30),with a statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Chuzhi Shengfa tablets and finasteride shows good clinical efficacy in treating male androgenetic alopecia.Additionally,Chuzhi Shengfa tablets are convenient to administer and effectively improve efficacy,significantly improving patients’conditions,and demonstrating good clinical application value.

Effectiveness of Chuzhi Shengfa Tablets Combined with Ketoconazole Shampoo and Chuzhi Shengfa Tablets Combined with 5%Minoxidil Foam in the Treatment of Male Androgenetic Alopecia

Objective:To investigate the clinical efficacy and safety of Chuzhi Shengfa Tablets combined with ketoconazole shampoo and Chuzhi Shengfa Tablets combined with 5%minoxidil foam in the treatment of male androgenetic alopecia.Methods:From July 2022 to July 2023,120 male patients with androgenetic alopecia were selected from our Department of Dermatology and randomly divided into Control Group 1,Control Group 2,Observation Group 1,and Observation Group 2,with 30 patients in each group.Control Group 1 was treated with ketoconazole shampoo,Control Group 2 with 5%minoxidil foam,Observation Group 1 with ketoconazole shampoo combined with Chuzhi Shengfa Tablets,and Observation Group 2 with 5%minoxidil foam combined with Chuzhi Shengfa Tablets.Hair density,hair diameter,scalp oil secretion(using oil secretion scoring),and adverse reactions were compared before and after treatment across the four groups.Results:After treatment,hair density and hair diameter significantly increased in all four groups compared to before treatment,while scalp oil secretion scores significantly decreased(P<0.05).The improvements in Observation Groups 1 and 2 were significantly better than those in Control Groups 1 and 2(P<0.05).No significant differences in the incidence of adverse reactions were observed among the four groups(P>0.05).Conclusion:Chuzhi Shengfa Tablets combined with ketoconazole shampoo and Chuzhi Shengfa Tablets combined with 5%minoxidil foam are both effective and safe for treating male androgenetic alopecia.These combinations can significantly improve hair growth and are worthy of clinical promotion.

Serum Gelsolin Levels in PCOS-Related Androgenetic Alopecia

Aim: To compare serum gelsolin levels of women with androgenetic alopecia with PCOS and patients with non-PCOS alopecia. Materials and Methods: A total of 30 PCOS patients who applied to our dermatology clinic with the complaint of hair loss and were diagnosed with androgenetic alopecia (AGA) were included in the study. Thirty patients who were not diagnosed with PCOS but were diagnosed with AGA were considered as the control group. Patients in the control group were matched with PCOS in terms of age. AGA was diagnosed in cases of widespread thinning of the hair on the scalp and preservation of the frontal hairline. All participants underwent a complete clinical examination and blood examination. Serum gelsolin levels of both groups were measured by ELISA. Results: The number, age, and BMI values of the participants in both groups were recorded as similar. Serum total testosterone, insulin, HOMA-IR and LH values were significantly higher in the PCOS with AGA compared to the AGA without PCOS. There is no significant difference between groups in terms of serum FSH levels. Serum gelsolin levels of the PCOS group were significantly lower than the control group (160.1 ± 34.2 ng/mL vs. 188.6 ± 46.7 ng/mL, p Conclusions: Serum gelsolin levels in PCOS patients with androgenetic alopecia were found to be significantly lower than in non-PCOS alopecia patient groups.

Defective Expression of the Gap Junction Protein Pannexin-1 Channel Contributes to the Formation of PCOS-Realted Androgenetic Alopecia

Objective: To determine serum pannexin-1 channel levels and their association with hair loss in women with PCOS diagnosed with female androgenetic alopecia (FAGA). Materials and Methods: Thirty-five women with PCOS who presented with diffuse and treatment-resistant progressive hair loss and were diagnosed with FAGA were included in the study. 25 patients who were diagnosed with female androgenetic alopecia but did not have PCOS were considered as the control group. PCOS and control groups were matched by age. Follicular miniaturization, displacement of terminal hairs with vellus hairs, and a diffuse decrease in hair density were accepted as FAGA in the trcihoscopy examination of the vertex and bitempoaral area. On the third day of the menstrual cycle serum FSH, LH, testosterone, PRL and insulin levels were measured. Insulin resistance was calculated with HOMA-IR. Serum pannexin-1 channel levels of each group were mesured with ELISA. Results: Serum pannexin 1 channels levels of FAGA group due to PCOS were found to be significantly higher than FAGA patients in the control group (2.72 ± 1.09 ng/mL vs 1.65 ± 0.97 ng/mL, p < 0.01). Serum LH, insulin and testosterone levels of PCOS group were significantly higher than controls. HOMA-IR values were significantly higher and >2.5 in the PCOS group compared to the controls. PRL values were similar except for one patient with elevated PRL. Serum FSH values were the same in both groups. A positive and significant correlation was found between pannexin 1 channels levels and HOMA-IR and serum testosterone levels (r = 0.650, p Conclusions: In addition to hyperandrogenemia, increased pannexin 1 channel levels may play a role in the etiology of PCOS associated FAGA, as it impairs the communication between the skin and hair follicle.

梅花针叩刺、针灸联合米诺地尔搽剂治疗男性脂溢性脱发疗效观察

目的:观察梅花针叩刺、针灸联合米诺地尔搽剂治疗男性脂溢性脱发的临床疗效。方法:选取2019年1月-2022年1月笔者医院收治的105例男性脂溢性脱发患者为研究对象,按随机数字表法分为对照组(n=52)和观察组(n=53),对照组给予针灸治疗,观察组在对照组基础上给予梅花针叩刺治疗。比较两组临床疗效、症状积分、发中微量元素水平、不良反应发生率及复发率。结果:共100例患者完成全部治疗。治疗后观察组总有效率为90.00%,显著高于对照组的68.00%(P<0.05);治疗后观察组脱发、瘙痒及脱屑积分均显著低于对照组(P<0.05);治疗后观察组头发中Fe、Cu、Zn水平均显著高于对照组(P<0.05),两组Ca水平比较差异无统计学意义(P>0.05);治疗后观察组复发率为4.00%,低于对照组的20.00%(P<0.05)。结论:梅花针叩刺、针灸联合米诺地尔搽剂治疗男性脂溢性脱发的临床疗效显著,能够减轻临床症状,改善发中微量元素含量,减少复发率。

1565 nm非剥脱点阵激光在雄激素性秃发中的临床疗效观察

目的探讨1565 nm非剥脱点阵激光联合外用米诺地尔及口服非那雄胺治疗雄激素性秃发(AGA)患者的效果及安全性。方法将75例Hamilton-Norwood分级Ⅱ—Ⅲ级男性AGA患者随机分为对照组1、对照组2和试验组,各25例。对照组1给予外用5%米诺地尔酊治疗,对照组2在对照组1基础上同时口服非那雄胺片,试验组除上述口服及外用治疗外,进行1565 nm非剥脱点阵激光治疗。在治疗前和治疗第24周时,采用7点总体评分量表评价毛发总体疗效;皮肤毛发镜测定毛发直径和毛发密度。治疗后调查患者满意度,并记录不良反应的发生情况。结果试验组毛发总体疗效优于对照组1和对照组2。治疗前,3组患者毛发直径和毛发密度差异均无统计学意义(P>0.05);治疗后,3组患者毛发直径和毛发密度均升高,试验组治疗后毛发直径和毛发密度均高于对照组1和对照组2(P<0.05)。试验组患者满意度优于对照组1和对照组2。试验组患者行激光治疗时出现可耐受的疼痛及灼烧感,症状均于数小时内自行缓解,各组均无严重不良反应发生。结论1565 nm非剥脱点阵激光、5%米诺地尔和非那雄胺联合疗法治疗AGA的疗效明显优于单纯使用米诺地尔和非那雄胺药物治疗。

雄激素性脱发的病因及发病机制研究进展

雄激素性脱发(AGA)是一种常见的脱发性疾病,发病机制复杂。目前对于AGA的机制研究仍聚焦于机体对雄激素的过度反应及遗传因素的影响。另外,毛发生长周期、头皮的血液流变学以及生活习惯在AGA的发病中也起到重要作用。本文对AGA病因及其发病机制进展作一综述,旨在为相关的治疗研究提供理论依据。

5%米诺地尔泡沫剂治疗男性雄激素性脱发患者临床疗效和安全性的观察

目的:观察5%米诺地尔泡沫剂用于中国男性雄激素性脱发患者的临床疗效和安全性。方法:通过随机双盲、RO-GAINE^(R)阳性对照的临床试验,入组Hamilton-Norwood分级为Ⅲv、Ⅳ、Ⅴ级且18~49岁的男性雄激素性脱发患者开展用药随访,共24周。结果:从毛发显微图像分析、全头毛发照相及专家评分、患者满意度自评及Hamilton-Norwood分级评估,5%米诺地尔泡沫剂和ROGAINE^(R)疗效差异无统计学意义(P>0.05)。两组不良反应发生率分别为19.0%和13.0%(P>0.05)。结论:5%米诺地尔泡沫剂治疗雄激素性脱发有效、安全。

重度斑秃的长期管理

斑秃是一种常见的非瘢痕性脱发,轻症有自愈倾向,而重度斑秃病程长、易复发,且与多种合并症相关,使得重度斑秃的治疗面临诸多挑战,给病人身心造成巨大负担。本文就斑秃治疗方案及病人的长期管理策略展开探讨,以期提高患者生活质量。

蔓柏生发方改善小鼠的雄激素性脱发可能与肠道菌群相关:基于16S rDNA分析

目的基于16S rDNA技术探索蔓柏生发方对雄激素性脱发(AGA)小鼠的肠道菌群影响。方法将36只C57BL/6小鼠随机分成6组:空白对照组、模型对照组、阳性药物组以及蔓柏生发方高、中、低组,每组6只。剔除所有小鼠脊背部2 cm×3 cm面积的毛发,除空白对照组外,其他组使用丙酸睾酮稀释液在小鼠背部脱毛区域进行皮下多点注射制备AGA模型,每只总剂量为0.1 mg/d。空白对照组和模型对照组在小鼠剃毛处外涂生理盐水,每只1.0 mL/d;阳性药物组涂5%米诺地尔酊,每只1.0 mL/d;蔓柏生发方高、中、低组分别灌胃不同浓度的蔓柏生发方(5.0 g/kg、2.5 g/kg、1.25 g/kg),连续给药30 d。30 d后留取脱毛区皮肤进行病理学观察,收集小鼠粪便进行16S rDNA分析。结果与模型组相比,蔓柏生发方组毛囊数量均明显增多,其中高剂量组可见毛囊呈现生长期样形态,接近空白组毛囊形态。多样性分析结果显示,与空白组比较,模型组肠道菌群丰富度、多样性明显下降,而蔓柏生发方对模型小鼠的肠道菌群丰富度有良好的上调作用,同时其作用具有浓度依赖性,高剂量组对菌群的调控作用最为显著。肠道菌群的α多样性指数在模型组与蔓柏生发方组之间存在显著差异(P<0.05)。结论蔓柏生发方能显著提高AGA小鼠肠道菌群的丰富度和多样性,其对AGA模型小鼠脱毛的治疗作用可能与其调节肠道微生物多样性有关。

维生素D衍生物卡泊三醇对小鼠斑秃治疗有效性及相关炎症因子的影响

目的 研究维生素D衍生物卡泊三醇对小鼠斑秃的缓解情况及对相关炎症因子的影响。方法 构建小鼠斑秃模型,将维生素D衍生物卡泊三醇均匀涂抹在小鼠斑秃区域后,观察小鼠斑秃缓解情况;同时,通过免疫荧光染色技术检测斑秃区域皮肤组织CD4^(+)、CD8^(+) T细胞和肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)等细胞因子情况。结果 卡泊三醇处理后小鼠斑秃完全消失,治疗有效率达100%;小鼠毛囊细胞周围与炎症反应相关的CD4^(+)和CD8^(+)T细胞数量降低,TNF-α、IL-6等炎症细胞因子分泌水平下降(P<0.05)。结论 卡泊三醇可通过抑制小鼠毛囊细胞周围与炎症反应相关的CD4^(+)和CD8^(+)T细胞数量以及TNF-α、IL-6等炎症细胞因子分泌而改善小鼠斑秃。

可溶性肿瘤坏死因子样凋亡弱诱导因子在斑秃病人血清及皮损中的表达及临床意义

目的检测可溶性肿瘤坏死因子样凋亡弱诱导因子(sTWEAK)在斑秃病人血清及皮损中的表达水平,并探讨其在斑秃发病过程中的作用及临床意义。方法以2017年10月至2018年11月在首都医科大学附属北京友谊医院确诊并治疗的斑秃病人70例为斑秃组,依据病情分为轻症组(44例)、重症组(26例)。同期该院因色素痣或皮肤良性肿瘤进行头皮手术的人群65例作为对照组。比较各组sTWEAK及相关细胞因子白细胞介素(IL)-4、IL-12、γ干扰素(IFN-γ)蛋白及mRNA表达水平;采用Pearson法分析两指标间相关性。多元线性回归分析各指标与sTWEAK或脱发严重度工具(SALT)评分的关系。结果斑秃组血清及皮损中sTWEAK表达水平[(196.73±32.48)ng/L,(2.35±0.62)ng/L]高于对照组[(121.75±19.62)ng/L,(1.49±0.45)ng/L](P<0.05)。斑秃组血清及皮损中细胞因子IL-12、IFN-γ表达水平高于对照组(P<0.05),IL-4表达水平比较差异无统计学意义(P>0.05)。斑秃病人血清及皮损中sTWEAK表达水平与IL-12及IFN-γ呈正相关,与IL-4表达水平无明显相关性。轻症组血清及皮损中sTWEAK[(173.25±26.84)ng/L,(2.04±0.57)ng/L]、IL-12及IFN-γ表达水平低于重症组[(236.47±42.02)ng/L,(2.87±0.70)ng/L](P<0.05);轻症组、重症组血清及皮损中IL-4表达水平差异无统计学意义(P>0.05);斑秃病人血清、皮损处sTWEAK、IL-12、IFN-γ与SALT评分均呈正相关(P<0.05)。多元线性回归分析显示,IL-12、IFN-γ与血清和皮损处sTWEAK呈显著正相关;血清及皮损处sTWEAK、IL-12、IFN-γ与SALT评分存在正相关性(P<0.05)。结论斑秃病人血清及皮损中sTWEAK表达水平增加,与IL-12及IFN-γ呈正相关,sTWEAK、IL-12及IFN-γ均与斑秃病情严重程度密切相关,sTWEAK可能参与斑秃炎症反应过程。

Janus激酶抑制剂治疗斑秃新进展

斑秃是一种慢性、免疫性、炎症性疾病,确切病因未明。重度斑秃难以治疗,严重影响患者生活质量。近年来,越来越多证据表明Janus激酶(JAK)抑制剂具有治疗斑秃的潜力,许多病例报道及大型病例系列研究证实JAK抑制剂治疗斑秃的疗效。2022年6月美国食品药品监督管理局(FDA)批准了巴瑞托尼用于治疗成人重度斑秃。JAK抑制剂通过JAK-信号传导及转录激活因子(STAT)通路阻断细胞因子的细胞内传递,从而抑制多种促炎细胞因子,还可能直接作用于毛囊上皮细胞,促进毛囊周期进入生长期。对于重症、激素治疗无效以及合并其他免疫性疾病的斑秃患者是一个新的选择。该文主要阐述JAK抑制剂的作用机制和口服及外用JAK抑制剂治疗成人以及儿童斑秃的现状。

Cronkhite-Canada综合征1例

报告Cronkhite-Canada综合征1例。患者男,68岁,因腹痛、腹泻3个月就诊。皮肤科检查:头发弥漫性稀疏,额顶部明显。上下唇部、双手部、双足底可见对称性弥漫性褐色色素沉着,其上多个绿豆大小的点滴状分布的黑色斑疹,趾指甲远端2/3断裂缺如,甲板表面粗糙、凹凸不平无光泽。双上眼睑及小腿出现凹陷性水肿。实验室检查:贫血、低蛋白血症。电子肠镜检查:结肠多发息肉。诊断:Cronkhite-Canada综合征。给予高蛋白等营养支持治疗和对症处理。治疗后贫血及低蛋白血症明显改善,肠息肉暂无复发。目前仍在进一步随访中。

超脉冲点阵CO_(2)激光联合5%米诺地尔酊治疗斑秃疗效分析

目的:研究超脉冲点阵CO_(2)激光联合5%米诺地尔酊治疗斑秃对患者外观美观度及毛发镜检查结果的影响。方法:选取2021年1月-2023年1月延安市人民医院收治的斑秃患者110例分为外用5%米诺地尔治疗的对照组(55例)和联合10600 nm超脉冲点阵CO_(2)激光治疗的观察组(55例),分组方法为随机抽签法,均治疗6周,后随访6个月。统计两组治疗6周后的临床疗效、随访期间复发情况及治疗期间不良反应发生情况,比较两组斑秃改善情况、外观美观度及治疗前和治疗6周后免疫、炎症指标、毛发镜检查、心理状态、脱发严重程度、生活质量。结果:治疗6周后,观察组总有效率为96.36%,高于对照组81.82%(P<0.05);随访期间,观察组复发率为9.09%,低于对照组23.64%(P<0.05)。观察组毳毛长出时间、毳毛变黑时间短于对照组,治疗6周后新发生长面积、美观度评分高于对照组(P<0.05)。两组治疗6周后外周血CD3^(+)、CD4^(+)水平、CD4^(+)/CD8^(+)、毛发密度、毛囊密度与治疗前比较,升高,观察组高于对照组(P<0.05);外周血CD8^(+)、血清肿瘤坏死因子α(TNF-α)水平、毳毛率及焦虑自评量表(Self-rating anxiety scale,SAS)、抑郁自评量表(Self-rating depression scale,SDS)评分、脱发严重程度评分工具(Severity of alopecia tool,SALT)、皮肤病生活质量指数(Dermatology life quality index,DLQI)评分与治疗前比较,降低,观察组低于对照组(P<0.05)。治疗期间,观察组总不良反应发生率为14.55%,对照组总不良反应发生率为9.09%,组间比较差异无统计学意义(P>0.05)。结论:超脉冲点阵CO_(2)激光联合5%米诺地尔酊可有效改善斑秃,提高患者生活质量,且复发风险低,安全性良好。

乌帕替尼治疗重度斑秃12例短期疗效观察

目的 观察乌帕替尼治疗重度斑秃的短期临床疗效及安全性。方法 纳入2023年3月—2024年3月河南科技大学第一附属医院皮肤科门诊12例重度斑秃患者,给予口服乌帕替尼缓释片治疗,12周后观察临床疗效和不良反应情况。结果 治疗12周后,脱发严重程度评估工具评分(SALT)≤20分的患者达到10例(83.33%);毛发平均密度由(29.42±3.23)根/0.46 cm^(2)增加至(35.50±2.87)根/0.46 cm^(2),差异有统计学意义(t=27.62,P<0.001);毛发平均直径由(39.58±2.35)μm增加至(67.75±6.43)μm,差异有统计学意义(t=14.26,P<0.001)。所有患者均未发生严重不良反应。结论 乌帕替尼治疗重度斑秃疗效显著,安全性好,可作为重度斑秃患者新的治疗选择。